Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases.
BBB
CNS diseases
Epigenetics
HDAC inhibitors
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Oct 2023
05 Oct 2023
Historique:
received:
15
05
2023
revised:
20
06
2023
accepted:
28
06
2023
medline:
19
7
2023
pubmed:
4
7
2023
entrez:
3
7
2023
Statut:
ppublish
Résumé
Many populations worldwide are suffering from central nervous system (CNS) diseases such as brain tumors, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease and Huntington's disease) and stroke. There is a shortage of effective drugs for most CNS diseases. As one of the regulatory mechanisms of epigenetics, the particular role and therapeutic benefits of histone deacetylases (HDACs) in the CNS have been extensively studied. In recent years, HDACs have attracted increasing attention as potential drug targets for CNS diseases. In this review, we summarize the recent applications of representative histone deacetylases inhibitors (HDACis) in CNS diseases and discuss the challenges in developing HDACis with different structures and better blood-brain barrier (BBB) permeability, hoping to promote the development of more effective bioactive HDACis for the treatment of CNS diseases.
Identifiants
pubmed: 37399711
pii: S0223-5234(23)00579-2
doi: 10.1016/j.ejmech.2023.115613
pii:
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Histone Deacetylases
EC 3.5.1.98
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
115613Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.